Alan J. Tackett Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy Federal Grant PI High Impact

IDeA National Resource for Quantitative Proteomics

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

Biochemistry & Molecular Biology, College of Medicine

ajtackett@uams.edu

51 h-index 284 pubs 10,428 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Alan J. Tackett's research focuses on understanding molecular mechanisms underlying cancer development and identifying potential therapeutic strategies. His work investigates the role of epigenetic modifications, protein interactions, and cellular processes, such as phase separation and chromatin looping, in tumorigenesis. Tackett has published research on various cancer-related molecular mechanisms, including the development of targeted therapies like PROTACs and the analysis of oncogenic nodes.

His research group at the University of Arkansas for Medical Sciences has explored specific molecular pathways involved in cancer, such as the regulation of MYC by NSD3 and the function of ZMYND11 in leukemogenesis. Tackett also investigates the interplay between the immune system and cancer, with studies on enhancing anti-tumor immunity through combination therapies. His scholarship includes work with animal models and human cell lines, utilizing techniques like mass spectrometry for proteomic analysis. Tackett is a principal investigator on federal grants and is recognized as a highly cited researcher, with a significant publication record and citation count. He collaborates with several researchers at the University of Arkansas for Medical Sciences, including Samuel G. Mackintosh, Aaron J. Storey, Stephanie D. Byrum, and Nathan L. Avaritt.

Metrics

h-index: 51
Publications: 284
Citations: 10,428

Selected Publications

Repurposing Monensin and Its Derivatives as Immune-Modulatory Candidates for Metastatic Breast Cancer (Abstract ID: 231537) (2026)

DOI OpenAlex
Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026)

DOI OpenAlex
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)

2 citations DOI OpenAlex
BAHCC1 binds H4K20me1 to facilitate the MCM complex loading and DNA replication (2025)

1 citation DOI OpenAlex
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025)

2 citations DOI OpenAlex
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)

1 citation DOI OpenAlex
The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators (2025)

18 citations DOI OpenAlex
Staphylococcus aureus Proteins Implicated in the Reduced Virulence of sarA and sarA/agr Mutants in Osteomyelitis (2025)

5 citations DOI OpenAlex
Dynamic global acetylation remodeling during the yeast heat shock response (2025)

1 citation DOI OpenAlex
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)

1 citation DOI OpenAlex
TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons (2023)

58 citations DOI OpenAlex
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023)

4 citations DOI OpenAlex
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model (2023)

24 citations DOI OpenAlex
Characterization of methionine dependence in melanoma cells (2023)

11 citations DOI OpenAlex
Oncogenic signaling-mediated regulation of chromatin during tumorigenesis (2023)

15 citations DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2021 ARA Fellow

Dr. Tackett leads a translational research team examining immunotherapy resistance in cancer treatment, specifically understanding why some patients show limited response to immunotherapies. His work combines research with clinical collaboration among oncologists, surgeons, and pathologists to develop new therapies for metastatic melanoma treatment.

Policy Impact

Advancing cancer immunotherapy research at the UAMS Rockefeller Cancer Institute, attracting federal funding and clinical collaborations that benefit cancer patients statewide.